July 14, 2023 SARC037 is Open and Accruing In a rare disease as Ewing sarcoma, we recognize we need to work together to complete important studies like this. Read more
February 2, 2023 From A Survivor’s Perspective My name is Caralynn Hampson and I am SARC’s Research and Development Intern. I’m also a Ewing’s sarcoma survivor and future biostatistician. Thank you for supporting SARC. Read more
June 29, 2022 SARC MEETING Recap Over 200 attend the SARC Semiannual Meeting at ASCO in Chicago. Read more
March 9, 2021 A message from SARC Medical Officer Scott Okuno: Open Clinical Trials Message (excerpt) from Dr. Okuno to SARC Members: SARC has several “open, active, enrolling clinical trials [including] extremity soft tissue sarcoma trial using radiation therapy and immunotherapy neoadjuvantly…for advanced metastatic … Read more
January 15, 2021 New Study in Ewing Sarcoma Open to Enrollment SARC037 is a phase I study protocol to determine the recommended dose of trabectedin given as a 1-hour infusion in combination with low dose irinotecan. All patients enrolled will receive trabectedin combination … Read more